Boehringer Navigates ‘Impractical’ Nintedanib Surveillance Plan In India
Executive Summary
Boehringer seeks tweaks in the surveillance plan for nintedanib in India amid disinclination among some physicians to participate in the study. Some experts though believe that the Indian regulatory apparatus should, in general, specify “strict guidance” on all protocol review requests.